| NCT06111014 | Continuation Study for Latozinemab | ENROLLING_BY_INVITATION | PHASE3 | 2023-12-08 | 2027-11-30 | 2027-07-30 |
| NCT05744401 | A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease | TERMINATED | PHASE2 | 2023-01-04 | 2025-01-31 | 2025-01-31 |
| NCT05053035 | A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS | TERMINATED | PHASE2 | 2021-09-02 | 2022-10-28 | 2022-10-28 |
| NCT04592874 | A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease | COMPLETED | PHASE2 | 2021-01-22 | 2024-09-12 | 2024-08-19 |
| NCT04374136 | A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3) | ACTIVE_NOT_RECRUITING | PHASE3 | 2020-07-23 | 2027-08-03 | 2025-09-01 |
| NCT04111666 | A Phase 1 First in Human Study to Assess Safety and Tolerability of AL101 | COMPLETED | PHASE1 | 2019-12-14 | 2022-06-09 | 2022-06-09 |
| NCT03987295 | A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2) | COMPLETED | PHASE2 | 2019-09-27 | 2024-06-05 | 2024-06-05 |
| NCT03822208 | First in Human Study for Safety and Tolerability of AL003. | COMPLETED | PHASE1 | 2019-03-29 | 2021-05-06 | 2021-05-06 |
| NCT03635047 | A Phase I Study for Safety and Tolerability of AL002. | COMPLETED | PHASE1 | 2018-11-12 | 2020-11-25 | 2020-08-03 |
| NCT03636204 | A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin (GRN) Mutation | COMPLETED | PHASE1 | 2018-09-14 | 2019-12-31 | 2019-12-31 |